This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fandi, A. Articles by Cvitkovic, E. Search for Related Content PubMed PubMed Citation Articles by Fandi, A. Articles by Cvitkovic, E.

Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type

From the Institut Gustave Roussy "La Grange," Savigny le Temple; Department of Radiotherapy, Institut Gustave Roussy, Cvitkovic and Associates, Consultants, and Hôpital Paul Brousse, Villejuif, France; Oncology Service, Rabat, Morocco; and Department of Oncology, Institut Sallah Azaiz, Tunis, Tunisia.

Address reprint requests to E. Cvitkovic, MD, Fédération des Services des Maladies Sanguines Immunitaires et Tumorales, Paul Brousse Hospital, 12-14 Avenue Paul-Vaillant Couturier, 94804 Villejuif Cedex, France; email e.cvitkovic{at}cvitkovic-ac.fr

PURPOSE: To review incidence and analyze profile of long-term complete responders among patients with undifferentiated carcinoma of nasopharyngeal type (UCNT) treated at a single institution.

PATIENTS AND METHODS: We present a cohort of 20 long-term unmaintained complete responders to chemotherapy for metastatic UCNT treated at the Institut Gustave Roussy between April 1978 and November 1996. A patient was considered a long-term survivor if he or she was disease-free for more than 36 months without treatment after obtaining a complete response by chemotherapy. Patient characteristics were as follows: sex, 17 men and three women; median age, 28 years (range, 9 to 62 years); median World Health Organization performance status, 1; and initial tumor-node-metastasis stage (International Union Against Cancer–American Joint Committee on Cancer, 1987) of T3 to T4, 60%, and of N2b to N3, 75%. Epstein-Barr virus serology was characteristic in 19 patients. Of 16 pretreated patients, 11 were pretreated by radiotherapy alone and five by chemotherapy and radiotherapy. Thirteen patients had metastatic relapses of locally controlled UCNT. Tumor sites were bone in 15 patients, lung in four, and liver (biopsy-proven) in two. Chemotherapy included the following: cisplatin, bleomycin, and fluorouracil in five patients; bleomycin, epirubicin, and cisplatin in seven patients; fluorouracil, mitomycin, epirubicin, and cisplatin in four patients; and fluorouracil, bleomycin, epirubicin, and cisplatin in one patient. Three patients were treated with platinum-based regimens before 1985. Patients received a median of six cycles (range, three to 13). Thirteen patients with bone metastases received consolidating radiotherapy.

RESULTS: As of June 1999, 14 of 20 patients were still alive with no evidence of disease after treatment (disease-free survival time, 82+ to 190+ months), three patients died of other causes while in complete response at 61, 109, and 208 months after treatment, and three patients died of disease at 42, 89, and 115 months after treatment. Long-term complete responses were obtained in both bone and visceral disease.

CONCLUSION: Our data support a curative role for chemotherapy in metastatic UCNT and are a major incentive to continue research for better combinations to increase the percentage of patients with metastatic UCNT who attain complete responses and long-term survival.

Presented at the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998.

This article has been cited by other articles:

				D. Chua, W. I. Wei, J. S.T. Sham, and G. K.H. Au Capecitabine Monotherapy for Recurrent and Metastatic Nasopharyngeal Cancer Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 244 - 249. [Abstract] [Full Text] [PDF]

				F.-Y. Liu, C.-Y. Lin, J. T. Chang, S.-H. Ng, S.-C. Chin, H.-M. Wang, C.-T. Liao, S.-C. Chan, and T.-C. Yen 18F-FDG PET Can Replace Conventional Work-up in Primary M Staging of Nonkeratinizing Nasopharyngeal Carcinoma J. Nucl. Med., October 1, 2007; 48(10): 1614 - 1619. [Abstract] [Full Text] [PDF]

				L. Licitra, P. Bossi, L. D. Locati, and C. Bergamini Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer? J. Clin. Oncol., October 20, 2005; 23(30): 7757 - 7758. [Full Text] [PDF]

				T.-C. Yen, J. T.-C. Chang, S.-H. Ng, Y.-C. Chang, S.-C. Chan, K.-J. Lin, W.-J. Lin, Y.-K. Fu, and C.-Y. Lin The Value of 18F-FDG PET in the Detection of Stage M0 Carcinoma of the Nasopharynx J. Nucl. Med., March 1, 2005; 46(3): 405 - 410. [Abstract] [Full Text] [PDF]

				T.-Y. Chen, H. H. W. Chen, W.-C. Su, and C.-J. Tsao High-dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients with Nasopharyngeal Cancer: a Feasibility Study Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 331 - 335. [Abstract] [Full Text] [PDF]

				T. P. Farias, F. L. Dias, R. A. Lima, J. Kligerman, G. M. de Sa, M. M. Barbosa, and F. B. Goncalves Jr Prognostic Factors and Outcome for Nasopharyngeal Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 794 - 799. [Abstract] [Full Text] [PDF]

				R.-L. Hong, L.-L. Ting, J.-Y. Ko, M.-M. Hsu, T.-S. Sheen, P.-J. Lou, C.-C. Wang, N.-N. Chung, and L. T. Lui Induction Chemotherapy With Mitomycin, Epirubicin, Cisplatin, Fluorouracil, and Leucovorin Followed by Radiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., December 1, 2001; 19(23): 4305 - 4313. [Abstract] [Full Text]